Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Weitere Synonyme anzeigen
Wählen Sie die gewünschte Spezies
Human HER2 Protein expressed in Human Cells - ABIN2001860
Yamamoto, Ikawa, Akiyama, Semba, Nomura, Miyajima, Saito, Toyoshima: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. in Nature 1986
Show all 9 Pubmed References
Human HER2 Protein expressed in Wheat germ - ABIN1353011
He, Qu, Shen, Tan, Zeng, Liu, Jiang, Li: Highly specific recognition of breast tumors by an RNA-cleaving fluorogenic DNAzyme probe. in Analytical chemistry 2015
Show all 2 Pubmed References
Human HER2 Protein expressed in HEK-293 Cells - ABIN2181216
Piechocki, Wu, Jones, Jacob, Gibson, Ethier, Abrams, Yagita, Venuprasad, Wei: Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. in International journal of cancer. Journal international du cancer 2012
Show all 4 Pubmed References
Human HER2 Protein expressed in HEK-293 Cells - ABIN2181214
NDong, Tate, Kett, Batra, Demidenko, Lewis, Hoopes, Gerngross, Griswold: Tumor Cell Targeting by Iron Oxide Nanoparticles Is Dominated by Different Factors In Vitro versus In Vivo. in PLoS ONE 2015
Show all 4 Pubmed References
Human HER2 Protein expressed in Human Cells - ABIN2001858
Lai, Lemke: An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. in Neuron 1991
Show all 6 Pubmed References
This trial did not clearly demonstrate that TC is non-inferior to dose-dense FEC --> D. However, 3-year DFS (zeige FST Proteine) rates were excellent in both arms for women with node-positive, HER2-negative early breast cancer.
In this study, both tumor-related and immune-related features contribute to the modulation of pCR after neoadjuvant chemotherapy plus anti-HER2 agents. Immune signatures rather than TILs added significant prediction of pCR beyond PAM50 intrinsic subtypes
Report localized therapy of ductal carcinoma in situ in mice using the immunoconjugate 225Ac linked-trastuzumab, which targets Her2, delivered through the intraductal route.
In HER2+ early breast cancer, a dual HER2-targeted combination of pertuzumab and trastuzumab, together with taxane-epirubicin-cyclophosphamide neoadjuvant chemotherapy, achieved high rates of pCR.
Tumor infiltrating lymphocytes cannot be used as a prognostic biomarker in pT1a-b HER2-positive breast cancer.
Data suggest ESE-1 (zeige ELF3 Proteine) silencing as a mean to treat HER2(+) patients who show resistance to anti-HER2 therapy.
Data show that HER2 breast cancer patients with good performance status, controlled extracranial (EC) metastasis and single brain metastasis (BM) had better outcome.
In this review the information regarding various epigenetic markers implicated in HER2 positive breast cancer susceptibility and therapeutic-strategies has been compiled. [review]
NRG1 (zeige NRG1 Proteine)/ErbB2/Src (zeige SRC Proteine)/PTK2 (zeige PTK2 Proteine) signaling pathway may be a novel regulator of keloid fibroblast migration.
Patients with triple-negative breast cancer have an increased serum HER2 concentration, and serum HER2 may be a valuable, novel biomarker for recurrence and metastasis in TNBC.
Results indicate the importance of the LDL receptor (LDLR (zeige LDLR Proteine)) in the growth of triple-negative and HER2-overexpressing breast cancers in the setting of elevated circulating LDL cholesterol (LDL-C).
immunocompetent mouse models of HER2/ErbB2-driven breast cancer, CD73 expression by tumor cells and host cells significantly suppressed immune-mediated responses mediated by anti-ErbB2 mAb.
We further demonstrate that loss of one allele of PTEN is sufficient to shift isoform dependency from p110alpha (zeige PIK3CA Proteine) to p110beta in vivo. These results provide insight into the molecular mechanism by which ErbB2-positive breast cancer escapes p110alpha (zeige PIK3CA Proteine) inhibition.
sought to further echocardiographically characterize the ErbB2(tg) mouse line as a model of hypertrophic obstructive cardiomyopathy
investigations revealed that NUMB (zeige NUMB Proteine) and NUMBL (zeige NUMBL Proteine) interacted with small GTPase (zeige RACGAP1 Proteine) Rab7 (zeige RAB7A Proteine) to transition ERBB2 from early to late endosome for degradation.
Combined targeting of TGF-beta (zeige TGFB1 Proteine), EGFR (zeige EGFR Proteine) and HER2 signaling suppresses lymphangiogenesis and metastasis in a pancreatic ductal adenocarcinoma model.
The conjugation of benzylguanine-modified auristatin F to EGFR (zeige EGFR Proteine)-specific 425(scFv)-SNAP and HER2-specific alphaHER2(scFv)-SNAP resulted in two potent recombinant antibody-drug conjugates that specifically killed breast cancer cell lines by inducing apoptosis when applied at nanomolar concentrations.
ErbB2 is required for neonatal cardiomyocyte proliferation. ErbB2 conditional knockout heart exhibited an upregulation of negative cell cycle regulators.
Despite previous evidence suggesting that ErbB (zeige EGFR Proteine) receptors can bind and activate IRSs, our findings indicate that ErbB2 does not cooperate with the IRS (zeige IARS Proteine) pathway in mouse breast cancer model.
It was suggested that transgenic HER-2/neu involves in initiation of malignization of mammary epithelial cells but also in acceleration of age-related hormonal and metabolic changes in turn promoting mammary carcinogenesis
Newly synthesized N-cadherin (zeige CDH2 Proteine) molecules move from the lateral to the basal surface of cardiomyocytes during trabeculation. This localization requires Erbb2 signaling.
these results suggest that Nrg1 (zeige NRG1 Proteine) is not the primary effector of trabeculation and/or that other EGF (zeige EGF Proteine)-like ligand(s) activates the ErbB2/ErbB4 (zeige ERBB4 Proteine) pathway, either through functioning as the primary ligand or acting in a redundant manner. Overall, our work provides an example of cross-species differences in EGF (zeige EGF Proteine) family member requirements for an evolutionary conserved process.
Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT (zeige AKT1 Proteine) signaling pathway governing the organization of a subset of epidermal cells during median fin fold morphogenesis.
A direct link was found between Erbb2 activity and remodeling of myofibrils.
Study shows that, in addition to its role in cardiomyocyte proliferation, ErbB2 is also required for regulating cardiomyocyte migration (delamination) to initiate cardiac trabeculation.
erbb3 (zeige ERBB3 Proteine) and erbb2 are essential for schwann cell migration and myelination in zebrafish.
NRG1 (zeige NRG1 Proteine) and PI3K functionally interact with ErbB2 and ErbB3 (zeige ERBB3 Proteine) during regeneration
Results indicated that most periocular squamous cell carcinomas of horses expressed epidermal growth factor receptor (EGFR (zeige EGFR Proteine)) and human epidermal growth factor receptor (zeige EGFR Proteine) 2 (HER2).[HER2]
Widespread expression of ErbB2 receptor mRNAs was found throughout the telencephalon of juvenile and adult monkeys with in situ hybridization, with higher levels in grey matter compared to white matter.
We have isolated the cDNA encoding the rhesus monkey homolog of human Her2/neu (RhErbB2) to construct DNA plasmids and adenoviral vectors for the development of a cancer vaccine against this protein.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
c-erb B2/neu protein
, metastatic lymph node gene 19 protein
, neuro/glioblastoma derived oncogene homolog
, neuroblastoma/glioblastoma derived oncogene homolog
, proto-oncogene Neu
, proto-oncogene c-ErbB-2
, receptor tyrosine-protein kinase erbB-2
, tyrosine kinase-type cell surface receptor HER2
, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
, Neu oncogene
, avian erythroblastosis oncogene B 2
, proto-oncogene NEU
, Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog)
, NEU proto-oncogene
, epidermal growth factor receptor-related protein
, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
, epidermal growth factor receptor type 2